2022艾滋病毒治疗的进展( 二 )


Current Opinion in HIV and AIDS: “Lenacapavir: a first-in-class HIV-1 capsid inhibitor.”
Nature Communications: “A functional map of HIV-host interactions in primary human T cells.”
IAVI: “Broadly neutralizing antibodies for HIV prevention.”
USFC: “AIDS treatments.”
【2022艾滋病毒治疗的进展】FDA: “FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection” “FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention.”

推荐阅读